CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 94 enrolled
Drug / intervention
Curcumin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03223883
NCT03223883Phase 2Completed
CompareCT.gov

Curcumin Supplementation for Improving Vascular and Cognitive Function in Chronic Kidney Disease

Diana Jalal·interventional·Posted Jul 21, 2017·Updated Oct 8, 2024

In Brief

A Phase 2 clinical trial evaluating Curcumin and Placebo for Chronic Kidney Diseases and Cognitive Decline. Completed, enrolled 94 participants across 1 site.

Detailed Summary

The proposed research is clinical study evaluating the therapeutic benefits of curcumin on vascular function in patients with chronic kidney disease (CKD). The study aims to establish that curcumin will improve endothelial function and reduce large artery stiffness by reducing oxidative stress and in conjunction with lowering markers of inflammation and oxidative stress. In addition, the study will evaluate the potential benefit of curcumin on cognitive function in patients with CKD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Diseases, Cognitive Decline
CountriesUnited States
CollaboratorsUniversity of Colorado, Boulder, Stanford University, University of Colorado, Denver

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJul 21, 2017
Enrollment StartJun 1, 2018
Primary CompletionJan 25, 2023
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 8.9 years ago

Interventions

Curcumindrug

Oral supplement for 12 months

Placeboother

Oral placebo for 12 months